Abstract
Pazopanib and sunitinib are tyrosine kinase inhibitors that can be used in the first-line treatment of patients with advanced or metastatic renal cell carcinoma. Both substances differ from each other in their selectivity and affinity for target receptors, which is related to their different efficacy, but also to the occurrence of some side effects.
Recently, the so-called PRO (patient-reported outcomes) substances, ie results reported by patients themselves, have been included among the traditional indicators of efficacy (frequency of objective treatment responses, length of survival) of substances evaluated in clinical studies. These primarily serve to understand the clinical significance of adverse reactions that are reported in association with the therapy being administered.